Report cover image

Global Viral Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 02, 2025
Length 197 Pages
SKU # APRC20106295

Description

Summary

According to APO Research, The global Viral Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Viral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Viral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Viral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Viral Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Viral Vaccines include GSK, Sanofi, Novartis, Merck, Pfizer, Bayer, Zoetis, Johnson and CSL, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Viral Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Viral Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Viral Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Viral Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Viral Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Viral Vaccines sales, projected growth trends, production technology, application and end-user industry.


Viral Vaccines Segment by Company

GSK
Sanofi
Novartis
Merck
Pfizer
Bayer
Zoetis
Johnson
CSL
AstraZeneca

Viral Vaccines Segment by Type

Attenuated Vaccine
Inactivated Vaccine

Viral Vaccines Segment by Application

Research Institute
Hospital
Pharmaceutical Factory
Others

Viral Vaccines Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Viral Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Viral Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Viral Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Viral Vaccines Market Size, 2020 VS 2024 VS 2031
1.3 Global Viral Vaccines Market Size Estimates and Forecasts (2020-2031)
1.4 Global Viral Vaccines Sales Estimates and Forecasts (2020-2031)
1.5 Global Viral Vaccines Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Viral Vaccines Market Dynamics
2.1 Viral Vaccines Industry Trends
2.2 Viral Vaccines Industry Drivers
2.3 Viral Vaccines Industry Opportunities and Challenges
2.4 Viral Vaccines Industry Restraints
3 Viral Vaccines Market by Manufacturers
3.1 Global Viral Vaccines Revenue by Manufacturers (2020-2025)
3.2 Global Viral Vaccines Sales by Manufacturers (2020-2025)
3.3 Global Viral Vaccines Average Sales Price by Manufacturers (2020-2025)
3.4 Global Viral Vaccines Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Viral Vaccines Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Viral Vaccines Manufacturers, Product Type & Application
3.7 Global Viral Vaccines Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Viral Vaccines Market CR5 and HHI
3.8.2 Global Top 5 and 10 Viral Vaccines Players Market Share by Revenue in 2024
3.8.3 2024 Viral Vaccines Tier 1, Tier 2, and Tier 3
4 Viral Vaccines Market by Type
4.1 Viral Vaccines Type Introduction
4.1.1 Attenuated Vaccine
4.1.2 Inactivated Vaccine
4.2 Global Viral Vaccines Sales by Type
4.2.1 Global Viral Vaccines Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Viral Vaccines Sales by Type (2020-2031)
4.2.3 Global Viral Vaccines Sales Market Share by Type (2020-2031)
4.3 Global Viral Vaccines Revenue by Type
4.3.1 Global Viral Vaccines Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Viral Vaccines Revenue by Type (2020-2031)
4.3.3 Global Viral Vaccines Revenue Market Share by Type (2020-2031)
5 Viral Vaccines Market by Application
5.1 Viral Vaccines Application Introduction
5.1.1 Research Institute
5.1.2 Hospital
5.1.3 Pharmaceutical Factory
5.1.4 Others
5.2 Global Viral Vaccines Sales by Application
5.2.1 Global Viral Vaccines Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Viral Vaccines Sales by Application (2020-2031)
5.2.3 Global Viral Vaccines Sales Market Share by Application (2020-2031)
5.3 Global Viral Vaccines Revenue by Application
5.3.1 Global Viral Vaccines Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Viral Vaccines Revenue by Application (2020-2031)
5.3.3 Global Viral Vaccines Revenue Market Share by Application (2020-2031)
6 Global Viral Vaccines Sales by Region
6.1 Global Viral Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Viral Vaccines Sales by Region (2020-2031)
6.2.1 Global Viral Vaccines Sales by Region (2020-2025)
6.2.2 Global Viral Vaccines Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Viral Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Viral Vaccines Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Viral Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Viral Vaccines Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Viral Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Viral Vaccines Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Viral Vaccines Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Viral Vaccines Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Viral Vaccines Revenue by Region
7.1 Global Viral Vaccines Revenue by Region
7.1.1 Global Viral Vaccines Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Viral Vaccines Revenue by Region (2020-2025)
7.1.3 Global Viral Vaccines Revenue by Region (2026-2031)
7.1.4 Global Viral Vaccines Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Viral Vaccines Revenue (2020-2031)
7.2.2 North America Viral Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Viral Vaccines Revenue (2020-2031)
7.3.2 Europe Viral Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Viral Vaccines Revenue (2020-2031)
7.4.2 Asia-Pacific Viral Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Viral Vaccines Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Viral Vaccines Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 GSK
8.1.1 GSK Comapny Information
8.1.2 GSK Business Overview
8.1.3 GSK Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 GSK Viral Vaccines Product Portfolio
8.1.5 GSK Recent Developments
8.2 Sanofi
8.2.1 Sanofi Comapny Information
8.2.2 Sanofi Business Overview
8.2.3 Sanofi Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Sanofi Viral Vaccines Product Portfolio
8.2.5 Sanofi Recent Developments
8.3 Novartis
8.3.1 Novartis Comapny Information
8.3.2 Novartis Business Overview
8.3.3 Novartis Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Novartis Viral Vaccines Product Portfolio
8.3.5 Novartis Recent Developments
8.4 Merck
8.4.1 Merck Comapny Information
8.4.2 Merck Business Overview
8.4.3 Merck Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Merck Viral Vaccines Product Portfolio
8.4.5 Merck Recent Developments
8.5 Pfizer
8.5.1 Pfizer Comapny Information
8.5.2 Pfizer Business Overview
8.5.3 Pfizer Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Pfizer Viral Vaccines Product Portfolio
8.5.5 Pfizer Recent Developments
8.6 Bayer
8.6.1 Bayer Comapny Information
8.6.2 Bayer Business Overview
8.6.3 Bayer Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Bayer Viral Vaccines Product Portfolio
8.6.5 Bayer Recent Developments
8.7 Zoetis
8.7.1 Zoetis Comapny Information
8.7.2 Zoetis Business Overview
8.7.3 Zoetis Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Zoetis Viral Vaccines Product Portfolio
8.7.5 Zoetis Recent Developments
8.8 Johnson
8.8.1 Johnson Comapny Information
8.8.2 Johnson Business Overview
8.8.3 Johnson Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Johnson Viral Vaccines Product Portfolio
8.8.5 Johnson Recent Developments
8.9 CSL
8.9.1 CSL Comapny Information
8.9.2 CSL Business Overview
8.9.3 CSL Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 CSL Viral Vaccines Product Portfolio
8.9.5 CSL Recent Developments
8.10 AstraZeneca
8.10.1 AstraZeneca Comapny Information
8.10.2 AstraZeneca Business Overview
8.10.3 AstraZeneca Viral Vaccines Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 AstraZeneca Viral Vaccines Product Portfolio
8.10.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Viral Vaccines Value Chain Analysis
9.1.1 Viral Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Viral Vaccines Production Mode & Process
9.2 Viral Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Viral Vaccines Distributors
9.2.3 Viral Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.